Supplemental online content for: Comparing Patient ...

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

Supplemental online content for:

Comparing Patient-Controlled Analgesia Versus Non-PCA Hydromorphone Titration for Severe Cancer Pain: A Randomized Phase III Trial

Rongbo Lin, MD; Sunzhi Lin, MD; Shuitu Feng, MD; Qingyi Wu, MD; Jianqian Fu, MD; Fang Wang, MD; Hui Li, MD; Xiaofeng Li, MD; Gaowang Zhang, MD; Yongzhi Yao, MD; Min Xin, MD; Tianyang Lai, MD; Xia Lv, MD; Yigui Chen, MD; Shangwang Yang, MD; Yubiao Lin, MD; Lixia Hong, MD; Zhenyu Cai, MD; Jianfeng Wang, MD; Gen Lin, MD; Shaowei Lin, MD; Shen Zhao, MD; Jinfeng Zhu, MD; and Cheng Huang, MD J Natl Compr Canc Netw 2021;19(10):1148?1155 eFigure 1: Median Accumulated Hydromorphone Consumption From the Start of Titration to TST eFigure 2: Median Accumulated Hydromorphone Consumption From the Start of Titration to Hour 24 eFigure 3: Median Number of Delivered Boluses eTable 1: Common Opioid Conversion Chart eTable 2: ESAS at Baseline and Hour 24 eTable 3: Frequency of Main Adverse Effects

? JNCCN--Journal of the National Comprehensive Cancer Network | Volume 19 Issue 10 | October 2021

Lin et al ? 1

A

25

20

P=.086

B

25

20

P=.009

C

25

20

P=.793

Dose of Successful Titration Dose of Successful Titration Dose of Successful Titration

15

15

15

10

10

10

5

5

5

0

PCA

Non-PCA

All Patients

0

PCA

Non-PCA

Opioid-Tolerant Patients

0 PCA

Non-PCA

Opioid-Na?ve Patients

eFigure 1. Median accumulated hydromorphone consumption from the start of titration to TST in the PCA versus non-PCA groups, respectively, for (A) all patients [1.0 mg (IQR, 0.5?2.0 mg) vs 1.5 mg (IQR, 1.0?2.5 mg); P5.086]; (B) opioid-tolerant patients [1.0 mg (IQR, 1.0?2.0 mg) vs 2.0 mg (IQR, 1.0?4.0 mg); P5.009]; and (C) opioid-na?ve patients [1.0 mg (IQR, 0.5?2.0 mg) vs 1.0 mg (IQR, 0.5?2.0 mg); P5.793]. Abbreviations: IQR, interquartile range; PCA, patient-controlled analgesia; TST, time to successful titration.

A

40

B

40

C

40

Dose Over 24 Hours Dose Over 24 Hours Dose Over 24 Hours

30

P=.600 20

30

P=.028 20

30

P=.048 20

10

10

10

0

PCA

Non-PCA

All Patients

0

PCA

Non-PCA

Opioid-Tolerant Patients

0

PCA

Non-PCA

Opioid-Na?ve Patients

eFigure 2. Median accumulated hydromorphone consumption from the start of titration to hour 24 in the PCA versus non-PCA groups, respectively, for (A) all patients [4.5 mg (IQR, 2.5?6.0 mg) vs 4.0 mg (IQR, 2.3?8.3 mg); P5.600]; (B) opioid-tolerant patients [5.5 mg (IQR, 2.5?8.3 mg) vs 6.3 mg (IQR, 4.0?12.0 mg); P5.028]; and (C) opioid-na?ve patients [4.0 mg (IQR, 2.5?5.5 mg) vs 2.5 mg (IQR, 2.0?4.3 mg); P5.048]. Abbreviations: IQR, interquartile range; PCA, patient-controlled analgesia.

| Volume 19 Issue 10 | October 2021

2 ? Lin et al

Injections/Presses (N) Injections/Presses (N) Injections/Presses (N)

A

16 12

8 4

P=.400

B

16 12

8 4

P=.687

C

16 12

8 4

P=.143

PCA

Non-PCA

All Patients

PCA

Non-PCA

Opioid-Tolerant Patients

PCA

Non-PCA

Opioid-Na?ve Patients

eFigure 3. Median number of delivered boluses in the PCA versus non-PCA groups, respectively, in (A) all patients [6 (IQR, 4?9) presses vs 6 (IQR, 4?9) boluses per patient; P5.400]; (B) opioid-tolerant patients [6 (IQR, 4?9) presses vs 7 (IQR, 4?9) boluses per patient; P5.687]; and (C) opioid-na?ve patients [7 (IQR, 4?9) presses vs 4 (IQR, 4?8) boluses per patient; P5.143]. Abbreviations: IQR, interquartile range; PCA, patient-controlled analgesia.

? JNCCN--Journal of the National Comprehensive Cancer Network | Volume 19 Issue 10 | October 2021

eTable 1. Common Opioid Conversion Chart

Opioid

Parenteral Dose

Oral Dose

Morphine Hydromorphone Oxycodone Fentanyla

10 mg 1.5 mg

-- 15 mcg/h

30 mg --

15?20 mg --

aFor transdermal patch conversions.

Lin et al ? 3

eTable 2. ESAS at Baseline and Hour 24

ESAS Item

PCA Median (IQR)

Baseline

Non-PCA Median (IQR)

P Value

PCA Median (IQR)

Hour 24

Non-PCA Median (IQR)

Total, n

106

108

105

107

Pain

8 (7?8)

8 (7?8)

.419

2 (2?2)

2 (2?5)

Tiredness

5 (4?6)

5 (4?6)

.718

2 (2?5)

3 (2?5)

Nausea

1 (1?1)

1 (0?2)

.158

2 (2?5)

3 (2?4)

Depression

3 (2?4)

3 (3?4)

.122

2 (2?3)

2 (2?4)

Anxiety

3 (3?4)

3 (3?4)

.570

2 (1?2)

2 (2?3)

Drowsiness

2 (2?3)

2 (1?3)

.182

2 (0?5)

2 (1?3)

Appetite

5 (4?6)

5 (4?6)

.555

5 (2?5)

5 (2?5)

Well-being

7 (6?7)

7 (6?7)

.759

5 (2?5)

5 (2?5)

Itching

1 (0?1)

1 (0?1)

.803

1 (0?2)

0 (0?2)

Dyspnea

2 (1?3)

2 (1?2)

.315

1 (1?2)

2 (1?2)

Overall score

36 (34?38)

37 (34?39)

.154

25 (16?29)

26 (19?35)

Abbreviations: ESAS, Edmonton Symptom Assessment System; IQR, interquartile range; PCA, patient-controlled analgesia.

P Value

.060 .129 .316 .107 .074 .827 .630 .458 .981 .173 .096

eTable 3. Frequency of Main Adverse Effects

Adverse Effect

PCA n (%)

Non-PCA n (%)

P Value

Total, n Constipation Nausea Vomiting Dizziness Pruritus Somnolence Dry mouth

106 5 (4.7) 7 (6.6) 2 (1.9) 2 (1.9) 4 (3.8) 3 (2.8) 5 (4.7)

108 4 (3.7) 10 (9.3) 3 (2.8) 4 (3.7) 3 (2.8) 5 (4.6) 3 (2.8)

.747 .615 1.000 .683 .720 .721 .699

Abbreviation: PCA, patient-controlled analgesia.

| Volume 19 Issue 10 | October 2021

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download